EMBOSS A Person-centred Integrated-care for Chronic Diseases in Patients of Low Socio Economic Status
EMBOSS
EMBOSS: Reach and Effect of a Person-centred Integrated-care Approach for Chronic Diseases and MultimorBidity in Patients of Low sOcio- Economic StatuS in General Practice
1 other identifier
interventional
540
1 country
1
Brief Summary
People of low socio economic status (SES) more often than others suffer from chronic diseases like diabetes mellitus, chronic obstructive pulmonary disease (COPD), or coronary diseases. Compared to others People of low SES more often have to deal with multiple diseases (multimorbidity) and experience worse health outcomes. The health literacy of people of low SES is often low. Current chronic disease management programs focus on reducing the burden of a single disease by prescribing medication, protocoled monitoring routines, or lifestyle advice. However, the effectiveness of these interventions is low in people with low SES, as the interventions insufficiently take into account the specific problems and needs of this (multimorbid) population. A person-centered and integrated-care approach, that puts the patient at the center of care instead of the disease and in which care is tailored to the individual patient with chronic disease(s), seems to be more appropriate, but only when low SES people are closely involved in the development, testing, and evaluation of such an approach. Also, certain preconditions should be met, such as training of specific knowledge and skills of the healthcare professionals involved. In the EMBOSS project, the investigators will develop, test, evaluate, and implement a person-centered integrated-care approach for and in close collaboration with people with low SES who have one or more chronic diseases. Thus, the EMBOSS study will have the potential to reducing health disparities in this group, to broadening the action perspectives of general practitioners and practice nurses for an increasing diverse patient population and to a better fit of lifestyle interventions in people of low SES.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 29, 2023
CompletedFirst Submitted
Initial submission to the registry
February 6, 2023
CompletedFirst Posted
Study publicly available on registry
August 2, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2024
CompletedSeptember 6, 2023
February 1, 2023
1.5 years
February 6, 2023
August 31, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
patient-reported health-related quality of life Physical Health
Global Physical Health \[Time Frame: Baseline, 6 months, 12 months\] Physical aspect of health-related quality of life as measured by the PROMIS-Global 10 instrument (T-scores; higher T-score indicates better physical aspect of HrQoL) Promis 10 is a patient-reported questionnaire in which the response options are presented as 5-point (as well as a single 11-point) rating scales.
12 months
patient-reported health-related quality of life Mental health
Global Mental Health \[Time Frame: Baseline, 6 months, 12 months\] Mental aspect of health-related quality of life as measured by the PROMIS-Global 10 instrument (T-scores; higher T-score indicates better mental aspect of HrQoL) Promis 10 is a patient-reported questionnaire in which the response options are presented as 5-point (as well as a single 11-point) rating scales.
12 months
Patient-experienced quality of care
atient-experienced quality of care \[Time Frame: Baseline, 6 months, 12 months\] Person-centredness of care as measured by the Person Centred Coordinated Care Experience Questionnaire (P3CEQ) instrument; minimum score 0, maximum score 30, higher score equals better P3CE.
12 months
Secondary Outcomes (9)
Patient activation as measured by PAM
Baseline, 6 months, 12 months
Health-related quality of life as measured by the EQ-5D-5L instrument
Baseline, 6 months, 12 months
BMI
Baseline, 6 months, 12 months
HbA1c
Baseline, 6 months, 12 months
Blood glucose
Baseline, 6 months, 12 months
- +4 more secondary outcomes
Study Arms (2)
Person-centred integrated care intervention
EXPERIMENTALThe core of the person-centered approach is a cyclical process and for EMBOSS developed for patients with low SES. The practice nurse in the GP will act as case manager and can consult other health providers. The first step in the intervention is assessing the integral health status of the patient (health across multiple domains), using a visual conversation tool. The second step is discussing the results with the patient. Personal goals are formulated in the third step. In the fourth step, the healthcare professional and patient will choose through shared-decision making the most appropriate interventions and support to achieve these goals, which are documented in a personal plan. Next, referrals are made if necessary and the treatment is started. An evaluation is planned and carried out. All practices in the EMBOSS intervention group will be trained by Pharos on how to recognize and provide GDM to low SES patients using appropriate communication skills and the specific tools.
Usual care
NO INTERVENTIONPractices in the control group provide care as usual, which consists of the SDM programmes according to the national care standards and General Practice guidelines (NHG) for DM2, COPD and CVD. According to these protocolised programmes, patients with COPD, CVD or DM2 visit their general practice at a standard frequency per year (1 - 4 times) and standard monitoring measurements and topics are discussed. The practices that are randomised to the control group will not receive any additional training related to this study.
Interventions
See arm description.
Eligibility Criteria
You may qualify if:
- Currently enrolled in any of the single disease management programmes (usual care) for DM2, COPD, asthma or CVD
You may not qualify if:
- Limited life expectancy (less than 3 months)
- Patients with high level of SES (or educational level \> MBO2)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
RadboudUMC
Nijmegen, Netherlands
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 6, 2023
First Posted
August 2, 2023
Study Start
January 29, 2023
Primary Completion
August 1, 2024
Study Completion
August 1, 2024
Last Updated
September 6, 2023
Record last verified: 2023-02